CA3230796A1 - Anti-transferrin receptor antibodies and uses thereof - Google Patents

Anti-transferrin receptor antibodies and uses thereof Download PDF

Info

Publication number
CA3230796A1
CA3230796A1 CA3230796A CA3230796A CA3230796A1 CA 3230796 A1 CA3230796 A1 CA 3230796A1 CA 3230796 A CA3230796 A CA 3230796A CA 3230796 A CA3230796 A CA 3230796A CA 3230796 A1 CA3230796 A1 CA 3230796A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
antibody
tfr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3230796A
Other languages
English (en)
French (fr)
Inventor
Isin DALKILIC-LIDDLE
Benjamin A. Smith
Karl J. M. Hanf
Fang QIAN
R. Blake Pepinsky
Thomas O. CAMERON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of CA3230796A1 publication Critical patent/CA3230796A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3230796A 2021-09-01 2022-08-31 Anti-transferrin receptor antibodies and uses thereof Pending CA3230796A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163239630P 2021-09-01 2021-09-01
US63/239,630 2021-09-01
US202263388088P 2022-07-11 2022-07-11
US63/388,088 2022-07-11
PCT/US2022/042196 WO2023034409A1 (en) 2021-09-01 2022-08-31 Anti-transferrin receptor antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CA3230796A1 true CA3230796A1 (en) 2023-03-09

Family

ID=83508506

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3230796A Pending CA3230796A1 (en) 2021-09-01 2022-08-31 Anti-transferrin receptor antibodies and uses thereof

Country Status (15)

Country Link
US (2) US11827702B2 (OSRAM)
EP (1) EP4396231A1 (OSRAM)
JP (1) JP2024534880A (OSRAM)
KR (1) KR20240107202A (OSRAM)
AU (1) AU2022340568A1 (OSRAM)
CA (1) CA3230796A1 (OSRAM)
CL (1) CL2024000642A1 (OSRAM)
CO (1) CO2024003577A2 (OSRAM)
CR (1) CR20240139A (OSRAM)
IL (1) IL311175A (OSRAM)
JO (1) JOP20240042A1 (OSRAM)
MX (1) MX2024002753A (OSRAM)
PE (1) PE20240895A1 (OSRAM)
TW (1) TW202328187A (OSRAM)
WO (1) WO2023034409A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120882749A (zh) * 2023-03-08 2025-10-31 渤健马萨诸塞州股份有限公司 抗转铁蛋白受体抗体及其用途
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법
CN116735864B (zh) * 2023-08-15 2023-11-10 迦进生物医药(上海)有限公司 评估TfR1抗体血液安全性的试剂盒
TW202517685A (zh) * 2023-10-26 2025-05-01 美商百健Ｍａ公司 抗運鐵蛋白受體抗體及其用途
CN121517563A (zh) * 2024-08-09 2026-02-13 东北制药集团股份有限公司 人源化的靶向TfR1的抗体及其应用
WO2026076250A1 (en) * 2024-10-03 2026-04-09 Genentech, Inc. Lipid nanoparticles for delivery to the cns from systemic administration

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
CA2081368A1 (en) 1990-03-27 1991-09-28 Ian S. Trowbridge Method for inhibiting cell growth and compositions useful therefor
US5648469A (en) 1992-04-20 1997-07-15 The Salk Institute For Biological Studies Monoclonal antibodies reactive with transferrin receptor cytoplasmic domain
WO2005094364A2 (en) 2004-03-31 2005-10-13 Chimeric Technologies, Inc. Iga antibody protein as a cytotoxic drug
CA2561830C (en) 2004-03-31 2013-05-21 Adnagen Ag Monoclonal antibodies with specificity for fetal erythroid cells
WO2005111082A1 (en) 2004-04-30 2005-11-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-tfr antibody.
AU2005252699B2 (en) 2004-06-07 2010-12-23 Macrogenics West, Inc. Transferrin receptor antibodies
CZ200755A3 (cs) 2004-07-26 2007-04-11 Biogen Idec Ma Inc. Peptidy protilátek anti-CD154
JP2008531060A (ja) 2005-03-04 2008-08-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド 相補性決定残基の合理的改変を介して免疫グロブリン可変領域をヒト化する方法
US7736647B2 (en) 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
FR2953841B1 (fr) 2009-12-16 2011-12-30 Centre Nat Rech Scient Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
FR2959416B1 (fr) 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
WO2012075037A1 (en) 2010-11-30 2012-06-07 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
CN103534272B (zh) 2011-05-09 2016-05-11 株式会社英仙蛋白质科学 能够特异性识别转铁蛋白受体的抗体
TWI450727B (zh) 2011-12-29 2014-09-01 財團法人工業技術研究院 抗人類輸鐵蛋白受體的單域抗體與其應用
US20130177579A1 (en) 2012-01-06 2013-07-11 Bioalliance C.V. Anti-transferrin receptor antibodies and methods using same
RU2711552C2 (ru) 2012-08-29 2020-01-17 Ф. Хоффманн-Ля Рош Аг Шаттл для гематоэнцефалического барьера
CA2893794C (en) 2012-11-08 2021-11-09 University Of Miyazaki Antibody capable of specifically recognizing transferrin receptor
WO2014144060A1 (en) 2013-03-15 2014-09-18 Alper Biotech, Llc Monoclonal antibodies to transferrin and transferrin receptor antigens, and uses thereof
EA038367B1 (ru) 2013-05-20 2021-08-16 Дженентек, Инк. АНТИТЕЛА ПРОТИВ РЕЦЕПТОРА ТРАНСФЕРРИНА (TfR) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
US9499628B2 (en) 2013-06-14 2016-11-22 Children's Hospital Medical Center Method of boosting the immune response in neonates
EP3450557A1 (en) 2013-12-25 2019-03-06 JCR Pharmaceuticals Co., Ltd. Novel anti-transferrin receptor antibody that passes through blood-brain barrier
JP6557664B2 (ja) 2014-01-06 2019-08-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 一価の血液脳関門シャトルモジュール
JP6779876B2 (ja) 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
IL310251A (en) 2015-05-04 2024-03-01 Cytomx Therapeutics Inc Anti-cd71 antibodies, activatable anti-cd71 antibodies, compositions comprising same and uses thereof
CR20210429A (es) 2015-06-24 2021-09-24 Hoffmann La Roche ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562)
KR20250073514A (ko) 2015-06-24 2025-05-27 제이씨알 파마 가부시키가이샤 혈액뇌관문을 통과하는 항인간 트랜스페린 수용체 항체
EP3325509B1 (en) 2015-07-22 2020-12-16 Inatherys Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders
TWI819458B (zh) 2015-10-02 2023-10-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
US20190240346A1 (en) 2016-06-20 2019-08-08 Genahead Bio, Inc. Antibody-drug conjugate
US20190375819A1 (en) 2016-10-29 2019-12-12 Rhode Island Hospital Glycosylated transferrin receptor 1 tumor antigen
NZ752703A (en) 2016-12-26 2022-09-30 Japan Chem Res Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
CN110506054A (zh) 2017-02-17 2019-11-26 戴纳立制药公司 经工程改造的多肽
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
HUE063021T2 (hu) 2017-08-10 2023-12-28 Denali Therapeutics Inc Mesterségesen elõállított transzferrin receptor-kötõ polipeptidek
CN118638788A (zh) 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
SG11202006433PA (en) 2018-02-05 2020-08-28 Jcr Pharmaceuticals Co Ltd Method for delivering drug to muscle
US20220378934A1 (en) 2018-08-02 2022-12-01 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof in treating muscle atrophy
CA3108287A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
MX2021001282A (es) 2018-08-02 2021-07-15 Dyne Therapeutics Inc Complejos dirigidos al músculo y sus usos.
JP7611825B2 (ja) 2018-08-02 2025-01-10 ダイン セラピューティクス，インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
EA202190418A1 (ru) 2018-08-02 2021-06-23 Дайн Терапьютикс, Инк. Мышечно-специфические комлексы и их применение в лечении прогрессирующей оссифицирующей фибродисплазии
EP3829594A4 (en) 2018-08-02 2022-05-11 Dyne Therapeutics, Inc. MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
US20210322562A1 (en) 2018-08-02 2021-10-21 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating centronuclear myopathy
CA3108285A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating pompe disease
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US20210308274A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating friedreich's ataxia
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
WO2021076856A1 (en) 2019-10-18 2021-04-22 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CA3163608A1 (en) 2020-01-10 2021-07-15 Romesh R. Subramanian Muscle-targeting complexes and uses thereof
IL294479A (en) 2020-01-10 2022-09-01 Dyne Therapeutics Inc Muscle targeting complexes and their uses for the treatment of myotonic dystrophy
US12624120B2 (en) * 2020-01-31 2026-05-12 Dyne Therapeutics, Inc. Anti-transferrin receptor (TfR) antibody and uses thereof
WO2022020105A1 (en) 2020-07-23 2022-01-27 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
CA3202832A1 (en) 2020-12-31 2022-07-07 Romesh R. Subramanian Muscle targeting complexes and uses thereof for treating myotonic dystrophy

Also Published As

Publication number Publication date
US20240158494A1 (en) 2024-05-16
PE20240895A1 (es) 2024-04-24
CL2024000642A1 (es) 2024-09-13
CO2024003577A2 (es) 2024-06-27
IL311175A (en) 2024-04-01
EP4396231A1 (en) 2024-07-10
US20230131379A1 (en) 2023-04-27
MX2024002753A (es) 2024-05-20
KR20240107202A (ko) 2024-07-08
JP2024534880A (ja) 2024-09-26
CR20240139A (es) 2024-06-14
US11827702B2 (en) 2023-11-28
AU2022340568A1 (en) 2024-03-28
WO2023034409A1 (en) 2023-03-09
JOP20240042A1 (ar) 2024-02-29
TW202328187A (zh) 2023-07-16

Similar Documents

Publication Publication Date Title
US11827702B2 (en) Anti-transferrin receptor antibodies and uses thereof
JP2024009004A (ja) Ｃ－ｋｉｔ抗体
AU2019201141B2 (en) Novel antibody binding to TFPI and composition comprising the same
RU2728858C2 (ru) Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью
CN118215682A (zh) 抗转铁蛋白受体抗体及其用途
KR20170023837A (ko) 인간화된 항-Tau(pS422) 항체 뇌 셔틀 및 이의 용도
CN115279787B (zh) 抗硬骨抑素构建体及其用途
US20170002097A1 (en) Multi-specific binding proteins
WO2019094576A1 (en) Bace-tau bispecific antibodies
WO2021026609A1 (en) Complement c2 binding proteins and uses thereof
KR101804988B1 (ko) 신규 항-tfpi 항체 및 이를 포함하는 조성물
CA3254085A1 (en) KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE
US12630616B2 (en) Complement C2 binding proteins and uses thereof
HK40112185A (zh) 抗硬骨抑素构建体及其用途
HK40111822A (zh) 抗硬骨抑素构建体及其用途
HK40111824A (zh) 抗硬骨抑素构建体及其用途
IL323104A (en) Antibodies against transferrin receptor and their uses
HK40112195A (zh) 抗硬骨抑素构建体及其用途
HK40111500A (zh) 抗硬骨抑素构建体及其用途
HK40113019A (zh) 抗硬骨抑素构建体及其用途
HK40083603B (zh) 抗硬骨抑素构建体及其用途
HK40083603A (en) Anti-sclerostin constructs and uses thereof
HK40076302B (zh) 新型多肽复合物
KR102284435B1 (ko) 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241216

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241216

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250724